Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabrice Andre

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
Nature Communications|October 4, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.
Nature Medicine|January 19, 2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trialThomas Bachelot, Thomas Filleron, Ivan Bieche, et al.
NPJ Precision Oncology|September 23, 2020
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave RoussyGonzalo Recondo, Linda Mahjoubi, Aline Maillard, et al.
Medical Image Analysis|November 10, 2020
AI-driven quantification, staging and outcome prediction of COVID-19 pneumoniaGuillaume Chassagnon, Maria Vakalopoulou, Enzo Battistella, et al.
Nature Cancer|June 30, 2025
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trialEdith Borcoman, Bastien Cabarrou, Miguel Francisco, et al.
Nature|September 7, 2022
Genomics to select treatment for patients with metastatic breast cancerFabrice Andre, Thomas Filleron, Maud Kamal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2019
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung CancerGonzalo Recondo, Laura Mezquita, Francesco Facchinetti, et al.
Science (New York, N.Y.)|August 22, 2020
Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophageAurélie Fluckiger, Romain Daillère, Mohamed Sassi, et al.
Cancer Discovery|August 5, 2022
Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder CancerAnne-Gaëlle Goubet, Leonardo Lordello, Carolina Alves Costa Silva, et al.
Nature|September 4, 2020
Pervasive chromosomal instability and karyotype order in tumour evolutionThomas B K Watkins, Emilia L Lim, Marina Petkovic, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
Nature Communications|October 4, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.
Nature Medicine|January 19, 2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trialThomas Bachelot, Thomas Filleron, Ivan Bieche, et al.
NPJ Precision Oncology|September 23, 2020
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave RoussyGonzalo Recondo, Linda Mahjoubi, Aline Maillard, et al.
Medical Image Analysis|November 10, 2020
AI-driven quantification, staging and outcome prediction of COVID-19 pneumoniaGuillaume Chassagnon, Maria Vakalopoulou, Enzo Battistella, et al.
Nature Cancer|June 30, 2025
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trialEdith Borcoman, Bastien Cabarrou, Miguel Francisco, et al.
Nature|September 7, 2022
Genomics to select treatment for patients with metastatic breast cancerFabrice Andre, Thomas Filleron, Maud Kamal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2019
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung CancerGonzalo Recondo, Laura Mezquita, Francesco Facchinetti, et al.
Science (New York, N.Y.)|August 22, 2020
Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophageAurélie Fluckiger, Romain Daillère, Mohamed Sassi, et al.
Cancer Discovery|August 5, 2022
Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder CancerAnne-Gaëlle Goubet, Leonardo Lordello, Carolina Alves Costa Silva, et al.
Nature|September 4, 2020
Pervasive chromosomal instability and karyotype order in tumour evolutionThomas B K Watkins, Emilia L Lim, Marina Petkovic, et al.
Pageof 15